The unanswered question: when to initiate antiretroviral therapy in children with HIV infection

被引:3
作者
Abrams, Elaine J. [1 ,2 ]
机构
[1] Columbia Univ, Harlem Hosp Ctr, New York, NY USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Programs, New York, NY USA
关键词
antiretroviral therapy; CD4; pediatrics; treatment guidelines; viral load;
D O I
10.1097/COH.0b013e3282cef1ee
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review The question of when to initiate antiretroviral treatment for children is perhaps the most critical unanswered question in pediatric HIV therapeutics. With large numbers of children throughout the world acquiring HIV infection and with improved global access to HIV treatment it is particularly timely to consider the optimal time to initiate antiretroviral therapy in infants, children and adolescents. Recent findings Early treatment can result in suppression of HIV viremia, immune preservation and prevention of disease progression. This must be balanced by the challenges of maintaining adherence to multidrug regimens, the risks of selecting drug-resistant virus, and long and short-term toxicities of medications. Summary This review provides a framework within which to consider when to initiate children on antiretroviral treatment. A child's age and developmental status, where they live, and the goals and expectations for treatment provide a context for balancing the risks of disease progression with the risks of drug-related toxicities and viral resistance.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 89 条
[1]  
Aboulker JP, 2004, AIDS, V18, P237, DOI [10.1097/00002030-200401230-00013, 10.1097/01.aids.0000111388.02002.6b]
[2]   Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants [J].
Abrams, EJ ;
Weedon, J ;
Steketee, RW ;
Lambert, G ;
Bamji, M ;
Brown, T ;
Kalish, ML ;
Schoenbaum, EE ;
Thomas, PA ;
Thea, DM .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01) :101-108
[3]   Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children [J].
Abrams, EJ ;
Wiener, J ;
Carter, R ;
Kuhn, L ;
Palumbo, P ;
Nesheim, S ;
Lee, F ;
Vink, P ;
Bulterys, M .
AIDS, 2003, 17 (06) :867-877
[4]  
[Anonymous], 2004, 7 REP JOINT NAT COMM
[5]  
[Anonymous], REP GLOB AIDS EP 200
[6]  
[Anonymous], 2002, NIH PUBL
[7]   Prospective study of human immunodeficiency virus 1-related disease among 512 infants born to infected women in New York City [J].
Bamji, M ;
Thea, DM ;
Weedon, J ;
Krasinski, K ;
Matheson, PB ;
Thomas, P ;
Lambert, G ;
Abrams, EJ ;
Steketee, R ;
Hegarty, M .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (10) :891-898
[8]  
Beral V, 2004, AIDS, V18, P51, DOI [10.1097/01.aids.0000096908.73209.5d, 10.1097/00002030-200401020-00006]
[9]   Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort [J].
Berk, DR ;
Falkovitz-Halpern, MS ;
Hill, DW ;
Albin, C ;
Arrieta, A ;
Bork, JM ;
Cohan, D ;
Nilson, B ;
Petru, A ;
Ruiz, J ;
Weintrub, PS ;
Wenman, W ;
Maldonado, YA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (18) :2221-2231
[10]   LONGITUDINAL-STUDY OF 94 SYMPTOMATIC INFANTS WITH PERINATALLY ACQUIRED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - EVIDENCE FOR A BIMODAL EXPRESSION OF CLINICAL AND BIOLOGICAL SYMPTOMS [J].
BLANCHE, S ;
TARDIEU, M ;
DULIEGE, AM ;
ROUZIOUX, C ;
LEDEIST, F ;
FUKUNAGA, K ;
CANIGLIA, M ;
JACOMET, C ;
MESSIAH, A ;
GRISCELLI, C .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1990, 144 (11) :1210-1215